Site Map The person in this role will work closely with the Director, Accounting and will partner with others in the Legal and People & Experience groups. It's important that everyone has the flexibility to work in the best way for them. Due to territory needs and proximity to customers, these positions are based in specific areas around the country. You are now leavingcareers.sagerx.comthe official site for Sage Therapeutics, Inc. About SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders. The biopharmaceutical company reported ($2.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.50) by $0.04. As you can clearly see from the Momentum Grade breakdown above, SAGE Therapeutics Inc is considered to have stronger momentum compared to Sarepta Therapeutics Inc. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, SAGE Therapeutics Inc could be a good stock to invest in. SageFlex offers all kinds of support across mental, physical, and emotional health. SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders. Sarepta Therapeutics Inc has a Earnings Estimate Score of 36, which is Negative. Sarepta Therapeutics Inc has a Value Score of 6, which is Ultra Expensive. Sage Therapeutics Could Be In For A Depressing FDA Review message, please email Aydanos a proteger Glassdoor y demustranos que eres una persona real. The concept is that the office is where you are. We focus our research and development efforts on modulation of GABA and NMDA receptorstwo critical neurotransmitter systems in the brain. It is all about flexibility for all Sageans! Sage Therapeutics Location: Greater St. Louis Experience: 22 years How to contact Katrina Paumier Get email address: kxxxxxxxxxxxxxr@sagerx.com Phone number: +1-xxx-xxx-7721 Last updated: 2022-12-17 Social media: Unlock Sage Therapeutics Inc profile and new opportunities for your business. Friendly staff who could cater for gluten free which is a rarity in this part of the world it. SAGE Therapeutics is searching for a patient-inspired, results oriented and collaborative sales professional for its Senior Therapeutic Business Manager (TBM), Psychiatry position. Maintain the software for our filings, interacting with auditors and partnering with our Legal group. We aim to discover new pathways to brain health by making medicines that matter so patients can get better, sooner. $1.1B Total Funding. Its other advanced product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder (MDD) and PPD. Data Provided by Refinitiv. Assist with SEC reporting by preparing disclosures including 10-Ks, 10-Qs, S-8s, and the proxy. Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. Experience with SEC reporting and equity accounting. Disculpa These will be clearly noted in the job descriptions. That can change as often as you want. Dysfunction in these two systems is known to be at the core of numerous psychiatric and neurological disorders. The candidate will work within the Electrophysiology and Neural Circuits team to support ongoing lead optimization and early research programs. learn more about our programs and research, discover the science behind our new approach to brain disorders, Submit Medical Information Requests for accurate and timely medical information, Learn about Sages funding and giving efforts and submit a grant or sponsorship request, View information on Sages clinical trials and pipeline. You will need to login before you can apply for a job. Sage Therapeutics | LinkedIn Edit Lists Featuring This Company Section, Sage Therapeutics to Present at the Stifel 2023 CNS Days, What 5 Analyst Ratings Have To Say About Sage Therapeutics, Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone, New England Companies With More Than 500 Employees. professionals, For the value investor looking to harness academic research in An ability to influence for greater outcomes. Ability to discuss financial concepts with a non-financial audience. This link will take you to another Sage Therapeutics, Inc. website. Possesses strong written and verbal communication skills. and entering a website that is not owned or controlled by Sage Therapeutics, Inc. Sage Therapeutics, Inc. makes no representation as to the accuracy of the information contained on websites it does not own or control. Sarepta Therapeutics Inc stock has a Value Score of 6, Momentum Score of 75 and Estimate Revisions Score of 36. The majority of jobs that will be eliminated primarily affect the company's commercial operations surrounding its one approved product, Zulresso, a treatment for postpartum depression. SAGE Therapeutics Inc does not currently pay a dividend. Hear it from us first when an exciting job opportunity opens up at Sage. real person. SAGE THERAPEUTICS, ZULRESSO and their respective logos, and SAGE CENTRAL are registered trademarks of Sage Therapeutics, Inc. All other trademarks referenced herein are the property of their respective owners. Sage Therapeutics Location Working from Home Start date Jun 30, 2023. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score. Scientific publications developed in collaboration with key experts. Friendly staff who could cater for gluten free which is a rarity in this part of the world it. Take a closer look at our talented teams. Accessibility verdade. Lamentamos pelo inconveniente. om ons te informeren over dit probleem. By continuing to use this website you agree to our, Notice of Pendency of Settlement of Action, Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference, Sage Therapeutics to Present at Upcoming May Investor Conferences, Goldman Sachs 44th Annual Global Healthcare Conference, 2023 RBC Capital Markets Global Healthcare Conference. Sarepta Therapeutics Incs trailing 12-month revenue is $975.7 million with a -114.3% net profit margin. Mix of work experience in both public accounting and industry. After all, if we're bringing our whole selves to work, we have to take care of each and every part. Sage is proud to support the work of researchers, scientists, medical professionals and organizations that are finding ways to help those in need and make a lasting, positive impact. Great location, although the car park isn't very big. SAGE Therapeutics Incs trailing 12-month revenue is $9.4 million with a % net profit margin. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. Neither SAGE Therapeutics Inc or Sarepta Therapeutics Inc has an Earnings Estimate Revisions Grade that could be considered a winner. Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. Our future of work model reflects this belief we call it SageFlex. General Scope and Summary. This role will work closely with the Director, Compliance Partnership & Operations to execute Sages field partnership strategy and engage in project management . document.write(CurrentYear) Pipeline - Sage Therapeutics var CurrentYear = new Date().getFullYear() At Sage, we believe we see possibilities where others do not and are working to find potential ways to treat people with brain health disorders. Caso continue recebendo esta mensagem, If you choose to work in one of our offices for four or more days per week, youll get an assigned desk. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53) and AMONDYS 45 (casimersen) Injection (AMONDYS 45). The Sage Medical Hub is a resource for licensed HCPs and other key stakeholders that provides access to Sages Global Medical Affairs team. Certified Public Accountant (CPA) license. Whether you want to work onsite, remotely, or a mix of both, you will enjoy the journey and have everything you need to do your best work.For those in the office, we are designing our office space with zones that will work for a variety of needs, allowing for team engagements, areas for health and well-being, and areas for quiet, focused work. Departments include Business Operations, Digital & Enterprise Capabilities, People & Experience, Finance, Legal, Compliance, Program Management, Investor Relations, and more. Were constantly pushing the boundaries to develop new medicines and to make the key breakthroughs that help us find potential ways to treat people with brain health disorders. Sage Therapeutics believes there are 18 million people in the U.S. suffering from postpartum depression and major depressive disorder, and management also believes that their current pipeline. Toggle Summary. Must thrive working in a fast-paced, innovative environment while remaining flexible, proactive, resourceful, and efficient. Als u dit bericht blijft zien, stuur dan een e-mail Sage Therapeutics last posted its quarterly earnings data on May 2nd, 2023. Location. Year-over-year quarterly sales growth most recently was 106.2%. If you continue to see this the official site for Sage Therapeutics, Inc. Sifting through countless of stocks in the Biotechnology & Medical Research industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. View more Discipline Information Technology, Business/Data Analytics Required Education . To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios. Sage Therapeutics, Inc. does not recommend and does not endorse the content of any third-party websites. Partners. As of June 29, 2023, SAGE Therapeutics Inc had a $2.8 billion market capitalization, compared to the Biotechnology & Medical Research median of $94.6 million.
